Loading stock data…
VCYT
$33.09+0.17 (+0.52%)
Market ClosedLast close May 1
Veracyte, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veracyte, Inc. in the Healthcare sector is trading at $33.09. The stock is currently 35% below its 52-week high of $50.71, remaining 6.8% below its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why VCYT maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$33.09
Potential Downside
55.2%
Whystock Fair Value$14.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$46.55+40.7%
Range$37.00 – $53.00
Fundamentals
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
41.11
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.01%
Volume
Today's trading volume
455,148
Recent News
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy Rating
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the most oversold healthcare stocks to invest in. Jefferies initiated coverage of Caris Life Sciences Inc. (NASDAQ:CAI) with a Buy rating on April 13, setting a $28 price target on the stock. The firm told investors that it sees “secular tailwinds” in the oncology diagnostics space from improving […]
Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals
If you are wondering whether Veracyte's current share price lines up with its underlying worth, this article walks through the key numbers that matter. The stock last closed at US$33.80, with recent returns of 8.7% over 7 days, 6.2% over 30 days, a 20.3% decline year to date, an 8.5% return over 1 year, a 46.1% return over 3 years, and a 31.6% decline over 5 years. Together, these figures present a mixed picture for anyone thinking about entry or exit points. These moves sit against a...
Is Veracyte Stock the Right Pick for Your Portfolio Now?
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.